Abstract: Trypanosoma cruzi proteases were object of intensive structural and functional characterization in the past decades. The celebration of the Chagas disease centenarian makes it opportune to review the foundations of molecular research on cruzipain, a major lysosomal cysteine protease. Acting as a virulence factor, cruzipain promotes intracellular parasitism. In addition, tissue culture trypomastigotes (TCTs) exploit the enzymatic versatility of cruzipain to liberate kinin peptides from kininogen molecules associated to heparan sulfate proteoglycans. Acting as paracrine agonists, the released kinins (eg, lysyl-bradykinin) potentiate parasite invasion of cardiovascular cells through the signaling of heterotrimeric G-protein coupled bradykinin receptors (BKRs). Generation of kinins also stimulates immunity, implying that cruzipain activity brings mutual benefits for the host-parasite relationship. Analysis of the dynamics of inflammation revealed that TCTs induce secretion of KC/MIP-2 by macrophages via signaling of Toll-like 2 receptors (TLR2). Acting on proximal microvascular beds, CXC chemokines evoke plasma extravasations by activating endothelium/neutrophils via CXCR2. Diffusion of plasma proteins (including kininogens) through extracellular matrices allow for cruzipain-dependent generation of vasoactive kinins, which then intensify interstitial edema through the activation of endothelial BK 2 R. Extent of edematogenic inflammation is counter-regulated by angiotensin converting enzyme (ACE), a kinin-degrading metallopeptidase. Acting at the interface between the vascular and the immune systems, kinins activate BK 2 R of dendritic cells, which then migrate to T-cell rich areas of secondary lymphoid tissues, where they induce immunoprotective type-1 effector T cells. Insight into the mechanisms regulating proteolysis in extravascular sites of infection may help to identify susceptibility markers of chronic heart disease.
INTRODUCTION
After decades of research, a large body of studies in humans [1] [2] [3] [4] and animal models [5] indicate that lowgrade/persistent tissue parasitism is the primary mechanism underlying chronic chagasic myocardiopathy (CCM). Albeit not excluding a secondary role for autoimmunity [6, 7] , this concept provides a solid framework to investigate the pathogenic roles of parasite antigens and pro-inflammatory molecules in CCM. During the course of chronic infection, there is sparse intracellular parasitism in the myocardium; hence the interstitial spaces are only sporadically exposed to intracellular T. cruzi released from disrupted host cells. Endowed with a moving flagellum, the freshly released trypomastigotes rapidly move away from the primary foci of infection, seeking for a safer (i.e., non-inflamed) environment to efficiently propagate the infection. In addition, depending on the interplay of host/parasite genetics, infected host cells may be prematurely killed, releasing variable numbers of amastigotes in the interstitial spaces. In contrast to the highly mobile trypomastigotes, the extracellular amastigotes (devoid of a moving flagellum) tend to cluster in the surroundings of the *Address correspondence to this author at the Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, CCS-Cidade Universitária, Rio de Janeiro, Brasil; Tel: +55-21-2209-6591; Fax: +55-21-2280-8193; E-mail: scharf@biof.ufrj.br primary infection foci, perhaps accounting for most, if not all, the sparse antigen deposits detected in heart specimens of CCM patients [2, 3, 8] . In the present article, I will discuss the hypothesis that infection-associated pathology may be aggravated as result of parasite-induced activation of proinflammatory proteolytic cascades.
Infection-Associated Vasculopathy May Contribute to CCM
Several decades ago, pathologists were intrigued by the findings that myocardial specimens from CCM patients often displayed diffused inflammatory infiltrates and evidence of extensive fibrosis in heart tissues despite the fact that pseudocysts were rarely found in such sections. As detection methods improved, researchers realized that a minor fraction of the intracellular parasites use multiple strategies [9] [10] [11] to subvert the selective pressure imparted by anti-parasite (type 1) effector CD8 + T cells [5] . In most patients, however, chronic infection does not lead to clinically active heart disease, implying that anti-parasite effector T cells may succeed at controlling intracellular parasite outgrowth in the myocardium without necessarily causing collateral damage. In approximately 30% of the patients, however, persistence of T. cruzi in the myocardium is associated with chronic immunopathology and fibrosis [12] . Studies in patients have linked severity of CCM to (i) increased myocardial infiltration by TNF--producing CD8 + T cells [1, 2, 13] (ii) higher frequency of parasite-specific IFN--producing CD4 + T cells in peripheral blood [14] . Analysis of IL-10 gene (promoter) polymorphism suggested that CCM may be a consequence of dysregulated T H 1-dependent pathology, presumably aggravated in patients that produce lower levels of the regulatory IL-10 cytokine [15] .
Proponents of the vascular theory have long argued that infection-associated microvascular lesions may build up over the years, inducing hypoxia and myocardial tissue injury. Accordingly, vasculopathy may converge with chronic immunopathology, thus intensifying the heart fibrosis that characterizes CCM [16] [17] [18] [19] . Tanowitz and co-workers have extensively investigated the mechanism underlying chagasic vasculopathy in mice infected with T. cruzi [20, 21] . Focusing on endothelin 1 (ET-1), a potent vasoconstrictor, these authors compared the outcome of chronic infection in wild type mice as compared to mice deficient in ET-1. Experiments conducted with ET-1 flox/flox ; -MHC-Cre(+) mice (in which the ET-1 gene was deleted from cardiac myocytes) and ET1flox/flox ; Tie 2 Cre (+) mice (in which the ET-1 gene was deleted from endothelial cells) showed that cardiac symptoms were only attenuated in the former group of ET-1 deficient animals [20] . Interestingly, inflammation scores were similar in all groups of infected mice, whereas chronic fibrosis was reduced in ET-1 flox/flox ; -MHC-Cre (+) mice. Furthermore, they noted a significant increase in the right ventricular internal diameter (RVID) of all infected mice, except for the ET-1 flox/flox ; -MHC-Cre (+) mice strain. In addition, all infected mice showed increased left ventricular and diastolic diameter, reduced fractional shortening, and decreased relative wall thickness, while ET-1 flox/flox ; -MHC-Cre (+) mice displayed less severe alterations [20] . Pooling results from magnetic resonance imaging and echocardiography, these authors proposed that clinical outcome of CCM may be worsened as result of ET-1 upregulation by cardiac myocytes [20] .
Parasite Molecules Involved in Endothelium Activation
In the early 80's, Libby and co-workers [22] reported that endothelial cells and cardiomyocytes underwent desialylation upon treatment with T. cruzi neuraminidase, an enzyme later characterized as a trans-sialidase (TS) [23, 24] . More recently, Todeschini, Mendonça-Previato and coworkers re-examined the interaction of TS with the endothelium [25] using a catalytically inactive form of recombinant TS. Accordingly, TS binds to endothelial cell surface molecules containing 2,3-linked sialic acid endothelium via the TS lectin binding site. In a subsequent study, these authors found that these catalytically inactive TS recombinant molecules activate NF-B, upregulate expression of adhesion molecules, and block apoptosis induced by growth factor deprivation [26] . Although not explored in the above mentioned studies, TS antigens shed by TCTs [27] may play a role in the microangiopathy observed in T. cruzi-infected animals [28] . Endothelium injury by antibody-mediated cellular cytotoxicity (ADCC) may also occur as result of cellsurface deposition of anti-TS IgG antibodies present in chagasic serum [29] . Alternatively, cardiovascular cells decorated with TS antibodies might be killed by complement mediated lysis.
Focusing on endogenous lipids of T. cruzi, Ashton and co-workers recently demonstrated that thromboxane A(2) (TXA2) are the predominant eicosanoids lipids [30] produced by this pathogen. Levels of TXA2 produced by amastigotes are significantly higher than those of trypomastigotes or epimastigotes. Notably, they also found that parasitederived TXA2 accounts for 90% of the circulating levels of TXA2 present in infected mouse [30] . TXA2 signaling seems to contribute to host resistance because mice deficient in the thromboxane receptor bear a highly susceptible phenotype [30] . Studies with endothelial cells revealed, however, that intracellular T. cruzi growth is hampered in cells deficient on TXA2 receptors. Together, these results suggest that parasite-derived TXA2 may have dual roles in the maintenance of host/parasite balance [30] . Another research line [39] indicated that T. cruzi synthesizes a platelet-activating factor (PAF)-like lipid that enhances differentiation of epimastigotes into metacyclic trypomastigotes. It remains to be determined if PAF-like lipids expressed by T. cruzi may play a role in pathogenesis.
It is well-established that T. cruzi can be sensed by sentinel cells of the innate immune system [32] [33] [34] [35] [36] [37] [38] [39] through germline encoded trans-membrane receptors of the TLR family. Although T. cruzi is empowered with 4 distinct TLR ligands [33] [34] [35] [36] [37] , two of these consist of lipid structures [33, 34] . Biochemical analyzes of mucin-linked glycosylphosphatidylinositol-anchors of TCTs (tGPI) identified the lipid acyl chain as the developmentally regulated microbial signature [37, 38] that elicits inflammation via TLR2 [32, 33] . Studies in macrophages from TLR deficient mice indicated that TLR2/TLR6 [32, 33, 36] , TLR4 [34] and TLR9 [36] are upstream regulators of the early proinflammatory cytokine response [32] . There is also evidence that TCTs activate NFkB and upregulate IL-1 production in cardiomyocytes via the TLR2 pathway [40] . Additional studies in mice showed that purified tGPI-mucin induced neutrophil accumulation in the mouse pleura via the TLR2/MCP-1 pathway [41] . As explained later on in this review, TCTs evoke interstitial edema via mechanisms involving cooperation between tGPI and parasite-derived cysteine proteases.
Foundations of Molecular Research on Cruzipain: A Brief Retrospective
Although there are excellent reviews on this subject [42] [43] [44] [45] , the centenarian of Chagas disease makes it opportune to describe how molecular research on cruzipain has evolved. In the late 80´s, research focused on seemingly unrelated T. cruzi molecules evolved in parallel in Rio de Janeiro, Buenos Aires and San Francisco before they converged. In 1983, Mendonça-Previato and co-workers characterized GP25, a glycoprotein with mucin-like properties (40% w/w carbohydrate) isolated from boiled extracts of epimastigotes [46] . Immunological studies soon revealed that GP25 was highly antigenic in the context of infection, because chronic chagasic patients usually presented high-titers of anti-GP25 IgG antibodies in the serum [47, 48] . Subsequent studies showed that GP25 was a proteolytic fragment arising from the cleavage of biosynthetic precursors of higher molecular mass (GP57/51) [49] . In 1989, Cazzulo and co-workers characterized the major lysosomal cysteine proteinase of epimastigotes as a cathepsin L-like enzyme, which they originally designated as "cruzipain" [50] . Shortly afterwards, the Nterminal sequence of GP57/51, combined to evidence from enzymatic studies, indicated that GP57/51 and cruzipain were either identical or closely related molecular entities [51, 52] , both of which localized to the flagellar pocket of the parasites. In a parallel study, Eakin, McKerrow, and coworkers [53] described the partial DNA sequence of a cathepsin L-like gene of T. cruzi. Additional DNA sequencing performed in Buenos Aires [54] revealed the presence of a 130 amino acids long carboxy-terminal extension (CTE/GP25) linked to the catalytic (central) domain through a post-translationally modified polythreonine hinge [55] that is sensitive to autocatalytic cleavage [49, 56] . In a major step forward, Eakin and co-workers [57] described the full-length sequence and organization of the cruzipain gene and expressed the enzymatically active form of the protease, truncated at the CTE. Synthesized as a single polypeptide chain, the pre-pro-enzyme undergoes maturation by proteolytic excision of the N-terminal pro domain, a feature shared by all papain-like enzymes [57] . Focusing their attention on the single N-linked glycan (Asn-255) of CTE, Parodi, Cazzulo and co-workers demonstrated presence of high mannose hybrid mono-antennary as well as complex bi-antennary oligosaccharide chains [58] .
The access to the full-length sequence of cruzipain had immediate impact in immunology research. In 1993, Arnholdt et al. [59] assayed human cruzipain-specific CD4
+ T H 1 cell lines with overlapping synthetic peptides spanning the cruzipain sequence. Although limited to a few chagasic patients, their data indicated that some human T cell epitopes were mapped to the catalytic domain of cruzipain [59] . Although the biochemical heterogeneity of the oligosaccharide chains of CTE/GP25 [58, 60] , and the polymorphism in the multicopy cruzipain gene family [61] posed difficulties for the characterization of epitopes recognized by patients' antibodies, Duschak have recently advanced the proposition that sulfate moiety present in the high-mannose type of oligosaccharide chain of the CTE [60] might be critical for antibody binding [45] .
Cruzipain, a Chemotherapeutic Target of T. cruzi
In 1992, Meirelles and co-workers [62] demonstrated that intracellular parasite growth in primary cultures of cardiomyocytes was arrested upon addition of Z-(SBz)CysPhe-CHN 2, a membrane-permeable irreversible inhibitor designed against cathepsin L. By treating heavily parasitized cardiomyocytes with a related radiolabeled probe, Z-PheTyr 125 -CHN 2, the Brazilian team showed that it bound irreversibly to cruzipain [62] . Independent studies confirmed these observations [63, 64] , providing the rationale for development of novel therapeutic drugs. In 1995, McGrath and co-workers [65] solved the X-ray structure of cruzipain complexed with irreversible inhibitors, starting the era of molecular medicine in Chagas disease. Among the novel inhibitors synthesized at UCSF [66] , Engel, Boyle and coworkers focused on K11777, a vinylsulfone derivative devoid of toxicity [67] . This drug completely eradicated T. cruzi from immunodeficient mice [68] and prevented heart damage in dogs [69] . Altogether, these studies provided proof of concept that cruzipain/cruzain inhibitors can be used as therapeutic drugs, at least so in the preclinical settings.
In a recent review, Caffrey and Steverding proposed a new terminology for kinetoplastid C1 peptidases [70] . Accordingly, the cathepsin L-like cruzain/cruzipain should be termed TcrCATL. Whichever the nomeclature to be adopted, it must take into account the fact that some cruzipain isoforms are not reasily categorized as proposed. For example, Lima and co-workers reported that recombinant cruzipain 2, an isoform encoded by a more divergent gene (88% identity) [71, 72] , displays a narrower substrate preference as compared to cruzipain 1 (TcrCATL). We ascribed the difference in substrate specificity of cruzipain 2 to presence of a few non-conserved substitutions in the S2 subsite, and to a minor extent, to substitutions found in the S 1 ' and the S 2 ' sites [73] . Of note, Mu-F-hF-VSPh, a potent inhibitor of recombinant cruzain (i.e., cruzipain 1), also inactivates recombinant cruzipain 2, albeit at reduced efficiency (Lima, APL and Scharfstein, J, unpublished data). Although cruzipain 2 is expressed in mammalian infective stages [72] , its functional role remains unknown. In addition to the closely related cruzipain 1 and 2 isoforms, the CL Brenner genome data [74, 75] show 3 additional members of the clan A of C1-family: a single copy gene encoding cathepsin B, which was only partially characterized [76, 77] , and two putative enzymes, respectively annotated as cathepsin S and bromelain-like protein.
Cysteine Proteases Drive Parasite Penetration in NonPhagocytic Host Cells
In 1985, Piras and co-workers reported that T. cruzi invasion of fibroblasts involved the participation of proteases [78] . Exploring the role of cruzipain (GP57/51) in these effects, Meirelles and co-workers [62] reported several years later that irreversible inhibitors designed for cathepsin L reduced the parasite ability to invade primary cardiomyocytes. Clues to understand the mechanisms of action of T. cruzi proteases emerged from studies conducted by Andrews, Burleigh and co-workers [79, 80] . While examining TCTs extracts, these authors found that oligopeptidase B was able to generate a soluble factor that induces elevation in the intracellular free Ca2 + concentration ([Ca   2+ ] i ) of mammalian cells. Transduced by pertussis toxin-sensitive seventransmembrane G-protein coupled receptors (GPCRs), the signal(s) generated by oligopeptidase B stimulated parasite entry via the Ca +2 /lysosomal pathway [81] [82] [83] . A few years later, studies performed with endothelial cells and cardiomyocytes showed that TCTs generated kinin peptides, which then enhanced parasite invasion through the signaled two alternative GPCR subtypes, BK 2 R or BK 1 R [84, 85] . Studies with synthetic and natural cruzipain inhibitors suggested that cruzipain molecules diffusing into the secluded sites formed by the juxtaposition of host/parasite plasma membranes might process cell-bound kininogens, releasing kinins within such synaptic sites [84] .
Originally described by Ming and co-workers [86] , the involvement of the TGF-B-dependent signaling pathway in parasite infectivity was recently revitalized [87] by the findings that TGF-blockers reduce mortality and cardiac damage in acutely infected mice in [88] . Although host proteases are able to activate latent (inactive) forms of TGF-under physiological conditions, Whanabi and co-workers [87] suggested that T. cruzi is also able to generate the active form of this cytokine via as yet uncharacterized leupeptin-sensitive T. cruzi protease(s) [87] . Although speculative, it is conceivable that parasite proteases confined to synaptic clefts might activate latent TGF-, as suggested for kinin generation. The multiplicity of proteolytic pathways that might drive host cell invasion by TCTs was further highlighted by the work of Santana and co-workers [89] appointing an in vitro role for POP Tc80 [89] , an 80 kDa prolyloligopeptidase that hydrolyzes human collagens type I/IV.
Strain-Dependent Variability of Infective Phenotype Correlated with Cruzipain Activity
Using a human myofibroblast cell line that does not express BK 2 R [82] Aparicio and co-workers [90] demonstrated that strain-dependent differences of parasite infectivity in vitro is causally linked to enzyme activity levels of cruzipain. After showing that TCTs-G (poorly infective) secreted low levels of active cruzipain enzyme as compared to TCTsDm28c, these authors rescued the infective phenotype of GTCTs by adding Dm28c TCT conditioned medium to the cultures. Importantly, the enhancement induced by Dm28 conditioned medium was abolished by the broad spectrum inhibitor E-64, thus implying that the enhancement was dependent on Dm28 cysteine protease activity. Of note, host cells pretreated with thapsigargin cancelled the effects of Dm28 conditioned medium, implying that signaling pathway involved mobilization of intracellular Ca 2+ stores. At least two functionally distinct cruzipain isoforms (Lima, AP, unpublished data) were detected in the Dm28c conditioned medium, but the lack of isoform-specific inhibitors has precluded an assessment of their individual roles in proteasemediated enhancement of G strain infectivity. Intriguingly, these authors pointed out that infection-promoting activity of Dm28c conditioned medium depends on an as yet unidentified membrane-bound factor [90] . It is still unclear whether cruzipain can liberate invasion-promoting factors from GPIlinked mucins [91] an/or from members of the GP85/TSfamily of antigens [92, 93] displayed on shed lipid vesicles [94] . Noteworthy in this context, Magdesian and co-workers [95, 96] recently demonstrated that synthetic versions of the FLY-containing peptide sequence of Tc85 (highly conserved in the Gp85/TS family) stimulates parasite entry in epithelial cells via mechanisms that involve (i) dephosphorylation of intermediate filaments, such as cytokeratin 18, and (ii) ERK1/2-dependent rearrangements of actin skeleton [96] . Future studies may determine if upon diffusion from flagellar pocket, lysosomal-like cysteine proteinases such as cruzipain I and/or cruzipain II may digest TS molecules that are either shed [94] and/or bound to host cell surfaces [25, 97] . Once released, the FLY-containing peptide may be either fit to stimulate parasite uptake by host cells, or may execute this function after undergoing trimming by host/parasite peptidases.
Molecular Interplay Between Cruzipain and its Endogenous Inhibitor, Chagasin, Influences the Infective Phenotype of T. cruzi
Tomas and Kelly were the first to report that the expression of the multicopy cruzipain genes is controlled posttranscriptionally [98] . In 2001, the characterization of chagasin as tight-binding endogenous cysteine protease inhibitor by Monteiro and co-workers [99] yielded clues to understand how the parasite regulates the enzymatic function of cruzipain in vivo [100] . Encoded by a single-gene, chagasin is a 110 amino acid-long single chain protein whose developmental expression is inversely correlated with cruzipain expression levels [99] . Recently classified in the MEROPS database as family 142, belonging to clan IX, chagasin is the prototype of a new family of cysteine protease inhibitors expressed in other protozoa and even in bacteria [101] . In agreement with earlier in silico predictions [102] , the NMR structure of the protein in solution [103] , followed by the Xdiffraction data of crystals made of chagasin either bound to falcipain [104] or complexed to papain [105] revealed the presence of an immunoglobulin-like domain scaffold projecting loops that interact with the active site of target cysteine proteases. Similar features were described for a chagasin orthologue of L. mexicana, operationally designated as inhibitor of cysteine peptidases (ICP) [106] .
Studies performed with biotinylated cysteine protease inhibitor or using specific antibodies demonstrated that cruzain/cruzipain transits the Golgi-endosomal pathway before being localized to pre-lysosomes/lysosomes in the posterior end of epimastigotes [107] . As reviewed elsewhere [108] , the ratio between the expression levels of chagasin and cruzipain molecules changes throughout T. cruzi development. Consistent with the stringent metabolic requirements of replicating forms, cruzipain levels are high in epimastigotes, while chagasin is reciprocally expressed at low levels [99] . In TCTs, however, the ratio of cruzipain/chagasin is markedly decreased, suggesting that lysosomal proteolysis is more tightly regulated in these (metabolic quiescent) infective forms [99, 100] .
Functional studies were performed using Dm28 parasites engineered to express 4-fold more chagasin than wild type. The results from this study showed that chagasin overexpression impairs biological functions that are typically linked to cruzipain activity, such as ability to invade myofibroblasts in culture systems [100] . Reminiscent of the results already described with the weakly infective G-strain TCTs [90] , the addition of conditioned medium derived from wild type Dm28c TCTs increased the infectivity of chagasin overexpressors [100] . Of note, the effect of Dm28 conditioned medium was blocked by irreversible cruzipain inhibitors, further suggesting that the deficient infective phenotype of chagasin overexpressors was due to impaired processing/secretion of active cysteine proteases [100] .
Santos and co-workers [100] showed that chagasin colocalized with cruzipain both in the Golgi complex and reservosomes of epimastigotes. In both organelles, the protein inhibitor was found as part of tight-binding molecular complexes with cruzipain [100] . Biochemical analysis suggested that chagasin inhibits the autocatalytic removal of the prosegment from pro-cruzipain zymogen(s), thereby exerting control a limiting step of cruzipain maturation in epimastigotes [100] . The titration of chagasin and of cruzipain levels in several T. cruzi strains revealed that the inhibitor/enzyme molar ratio in epimastigotes is kept fairly constant (~1:50) despite strain-dependent variability in the expression of the individual proteins [100] . Of note, however, G strain parasites display drastically reduced cysteine protease activity, although the expression of chagasin remains normal. The mechanism underlying this deficiency in active cruzipain remains to be clarified. Mature forms of cruzipain 2 are able to process pro-cruzipain I [100] , suggesting that the transactivation process originally described for L. mexicana cysteine proteases [109] may also occur in T. cruzi. It will be interesting to know if the poorly infective T. cruzi G-strains has deficient ability to trans-activate pro-cruzipain, perhaps reflecting reduced expression and/or production of unstable cruzipain isoforms. Whichever the explanation, these studies suggested that the strain-dependent changes in infective phenotype may reflect deficient cruzipain maturation at early stage of trafficking and/or dampening of active enzyme by chagasin.
TCTs Exploit the Kinin-Releasing Activity of Cruzipain to Invade Host Cells Via the GPCR/Ca

2+
/lysosomal Pathway
The term "kinin" refers to a small group of nona/decapeptides proteolytically excised from an internal portion of high or low molecular weight kininogens (HK/LK) by the action of specialized proteases, collectively referred as "kininogenases" [110] . Once released, the shortlived kinins (half life of <15 sec in the plasma) exert their biological effects by the paracrine mode, through the activation of distinct sub-types of heterotrimeric GPCRs, BK 2 R (constitutively expressed) and BK 1 R (induced in injured/inflamed tissues) [111] . While intact kinins (BK or LBK) are the agonists for BK 2 R, the ligand for the inducible BK 1 R is [des-Arg]-bradykinin or [des-Arg]-lysyl-BK, i.e., the truncated peptides generated by the removal of the Cterminal Arginine from the BK/LBK by carboxypeptidase N/M, i.e., kininase I. Long-range effects on BK 2 R localized at the vascular lining are prevented by the metabolic action of kinin-degrading peptidases, such as the angiotensin converting enzyme (ACE) [112] .
In the physiological settings, plasma kallikrein releases the nonapeptide bradykinin (BK) from HK, whereas tissue kallikrein liberates lysyl-BK from HK/LK [110] . Bacterial pathogens, such as Porphyromonas gingivalis, the gramnegative bacteria that causes gingival inflammation and periodontitis, can directly activate the kinin system through the activity of gingipains, a class of cysteine protease that is insensitive to inhibition by the cystatin-like domains of kininogens [113, 114] . Although the kinin peptides have been traditionally viewed as classical mediators of acute inflammation (e.g., inducers of edema formation, vasodilation and pain sensations), we have recently demonstrated that bradykinin is an endogenous danger signal that steers T H 1 polarization through the activation of conventional CD11c + DCs [115] . Consistent with these findings, studies in mice infected by P. gingivalis [114] or by T. cruzi [116] [117] [118] [119] demonstrated that kinins released in extravascular infections sites act as a bridge between inflammation, innate immunity and adaptive (T-cell dependent) immunity development. Another recent precedent that kinins stimulate T cell dependent acquired immunity came from studies in mice infected with Listeria [120] .
In the late 90's, Del Nery, Juliano and co-workers observed that cruzipain could efficiently hydrolyze synthetic peptides that corresponded to the flanking side bonds of lysyl-bradykinin, an internal decapeptide of kininogens [121] .
Encouraged by these biochemical observations, these workers demonstrated that cruzipain could release kinins, albeit slowly, from soluble forms of purified kininogens [121] . Initially, the concept that cruzipain could acts as a kininreleasing enzyme ("kininogenase") seemed paradoxical because kininogens display a cystatin-like domain overlapping with a cell-attachment site, i.e., soluble kininogens function as tight-binding active site inhibitors of papain-like proteases, such as cruzipain [122] . However, kinetic studies indicated that HK degradation by cruzipain was facilitated by cooperative interactions of heparan sulfate proteoglycans with both the HK substrate and the parasite protease [123] . We then examined if TCTs (Dm28 strain) could activate the kinin system in the biological settings. Using host cell invasion as a read-out, we demonstrated that living TCTs (Dm28c) rely on the kinin-releasing activity of cruzipain to infect cells that naturally overexpress BKRs, such as human umbilical vein endothelial cells (HUVECs) and cardiomyocytes [84] [85] [84, 85, 112] . However, the host protective effects of ACE were not manifested if the parasites were cultivated with TLR4-activated HUVECs [85] . Under these conditions, the TCTs can invade the activated HUVECs via the inducible BK 1 R pathway, irrespective of ACE [85] . Of note, inhibitors of carboxypeptidase M/N (kininase I) blocked the BK 1 R-dependent pathway of host cell invasion, suggesting that the primary kinin agonist released from cell-bound kininogens (by cruzipain) is rapidly converted into the truncated BK 1 R ligand, [des-Arg]-kinins by carboxypeptidase N/M (kininase I) [85] . In conclusion, these studies suggested that BK 1 R upregulation by host cells exposed to parasite proinflammatory molecules and/or to endogenous inflammatory signals might offer a window of opportunity for parasite invasion via signaling of the ubiquitous BK 1 R pathway [85] .
Kinins Released by Cruzipain Link Inflammation to Type-1 Immunity
Strategically positioned in peripheral tissues and in secondary lymphoid organs, the sentinel cells of the innate immune system sense the presence of pathogens through different types of pattern-recognition receptors. While much emphasis has been placed on the studies of the vascular functions of kinins, their innate effector roles remain virtually unknown. A few years ago, we reported that exogenous BK potently induces dendritic cell (DC) maturation, driving IL-12-dependent T H 1 responses through the activation of BK 2 R [115] . While these studies were in progress, we initiated studies in mice models of infection to evaluate if kinins could act as a bridge between inflammation and innate/adaptive immunity. To this end, we infected mice with pathogens that are empowered with kinin-releasing cysteine proteases, e.g., T. cruzi and P. gingivalis [114, [116] [117] [118] . Although the bulk of information about host resistance to acute T. cruzi infection was generated in systemically infected (i.p. route) mice [39, 117] , it is technically difficult to study the dynamics of early-phase inflammation under these experimental conditions. Monteiro and co-workers [116] overcame this limitation by injecting the kininreleasing pathogen in tissues that permit assessement of edematogenic inflammation. In the case of periodontal infection by the gram-negative anaerobic bacteria P. gingivalis, the pathogen was injected intramucosally (mandibular vestibule) [114] while in the case of T. cruzi the flagellated protozoa was injected in the mouse paw [116, 118] . In order to potentiate kinin system activation in mice subcutaneously infected with T. cruzi, the naïve mice were pre-treated with a single-dose of ACE inhibitor (captopril). As already explained, the ACE blocker increases the half-life of kinins liberated in the infected paw tissues, and these effects translate into increased BKR-dependent edema [85, 116] . Importantly, TCTs failed to evoke edema responses in BK 2 R-deficient mice, or in animals pre-treated with the BK 2 R antagonist HOE-140, irrespective of the captopril administration [116] . Notably, TCTs pretreated with Z11777 (cruzipain inhibitor) were uncapable of evoking BK 2 R-dependent edema in mice pretreated with ACE inhibitors [116] . These results indicated that TCTs induce edematogenic inflammation in cruzipain> BK 2 R-dependent manner while ACE, countermodulates these effects [85, 116, 118] .
At first sight it seemed surprising that mice injected with epimastigotes did not develop significant edema in animals pretreated with ACE inhibitors [85, 116] because these insect-stage parasites were known to secrete high-levels of cruzipain. Pertinently, mice injected with purified (activated) cruzipain also failed to develop appreciable edema, thus indicating that cruzipain enzyme activity (in TCTs) was necessary but not sufficient to induce edema via the kinin/BK 2 R pathway. The explanation for the discrepant phenotypes of TCTs and epimastigotes emerged as purified tGPI and cruzipain were injected alone, or combined, in the mouse paw [116] . These experiments showed that tGPI (TLR2 ligand) combined to cruzipain developed potent edematogenic inflammation in captopril-treated wild type mice but failed to evoke these responses in mice pretreated with HOE-140, in BK 2 R -/-or in TLR2 -/-mice. Consistent with these results, TCTs failed to evoke significant paw edema in captopril-treated TLR2 -/-mice, or in neutrophildepleted animals [116, 118] . Collectively, these results suggested that parasite-induced activation of TLR2 neutrophils is a pre-requisite for activation of the kinin system via the cruzipain kinin/BK 2 R-dependent pathway. Using intravascular microscopy in the hamster cheek pouch, Monteiro and co-workers [116] studied the early-phase microvascular responses elicited by topically applied TCTs. In contrast to epimastigotes, which failed to induce plasma leakage through post-capillary venules, these workers observed that leukocytes adhere to the endothelium shortly before the onset of plasma leakage. Schmitz and coworkers [118] turned to the mouse model to characterize the role of CXC chemokines in the TLR2-dependent inflammation (paw edema) ignited by TCTs. Their results indicated that TCTs initiate inflammation by inducing TLR2-dependent secretion of CXC chemokines in tissue resident macrophages [118] . Acting on proximal microvascular beds, KC/MIP-2 activates CXCR2 expressed by neutrophils/endothelium. A discrete leakage of plasma occurs, allowing for the accumulation of plasma-borne proteins, including kininogens, in the peripheral sites of infection. Further downstream, TCTs rely on cruzipain to degrade kininogens bound to heparan sulfate proteoglycans, releasing the short-lived kinins in extravascular sites of infection. As the concentrations of kinins rises, the interstitial edema is further increased as result of activation of endothelium BKRs [85, 116, 118] . Tightly regulated by ACE, the interstitial edema controlled by BK 2 R amplifies the early-phase of inflammation ignited by the activation of TLR2 CXCR2 /neutrophils [116, 118] .
After dissecting the role of TLR2/CXCR2/BK 2 R in the dynamics of inflammation elicited by TCTs, we then examined if immature DCs residing in interstitial tissues could sense the proteolytically released kinin "danger" signals via BK 2 R. This question was initially addressed by isolating CD11c + DCs rom the draining lymph nodes of wild type infected mice pretreated with ACE inhibitor. In line with our working hypothesis, Monteiro and co-workers [116] found that the frequency of IL-12-producing DCs were sharply increased in kinin/B 2 R-dependent manner. Prompted by these findings, Monteiro and co-workers [116] then asked if kinin/B 2 R-dependent induction of IL-12-producing CD11c + DCs was linked to upregulated adaptive (type-1) immune responses. The analysis of cytokine profile of Agspecific T cells isolated from draining lymph nodes confirmed that BK 2 R was critically involved in the induction of T H 1 responses in wild-type mice pretreated with captopril. Interestingly, injection of epimastigotes (which, as mentioned, fails to activate the kinin system because they lack potent TLR2 ligands) did not stimulate type-1 immunity via the BK 2 R pathway, despite ACE inhibitor administration [116] . As predicted, T. cruzi injection in neutrophil-depleted mice, in TLR2-deficient mice or in B 2 R-deficient mice did not lead to development of type-1 effector T cells. Importantly, the deficient type-1 immune responses observed in TLR2-deficient mice and neutrophil-depleted mice was rescued by injecting TCTs along with exogenous kininogen (HK). Controls showed that HK-dependent reconstitution of type-1 responses in the TLR2/neutrohil-deficient mice was nullified in mice pretreated with HOE-140 [116] . Furthermore, mice injected with purified HK combined to TCTs pre-treated with cruzipain inhibitors also failed to restore type-1 responses via the kinin/BK 2 R pathway. Collectively, the experiments performed in the s.c. model of T. cruzi infection demonstrated that endogenously released kinins, rather than TLR2 ligands of TCTs, are the downstream effector innate signals that guide T H 1 development [116] . The evidence that the TLR2/BK 2 R axis provides a bridge between inflammation to adaptive immunity was recently confirmed in a mouse gingivitis model induced by the gram-negative bacterium P. gingivalis [114] . Armed with potent kinin-releasing cysteine proteases (gingipains), this periodontopathogen spontaneously induce type-1 immune responses via the TLR2 neutrophil/ BK 2 R pathway, i.e., there was no need to artificially interfere with kinin homeostasis through the administration of ACE inhibitors, as done in the s.c. model of T. cruzi infection [116] .
Summarizing the informational content of this section, the data obtained in the subcutaneous model of T. cruzi infection support the notion that activation of the kinin system in extravascular sites of infection increases the intensity of inflammation ignited via the TLR2/CXCR2/ neutrophil pathway. Although the raise of kinin "danger" signals may lead to the maturation of conventional CD11c + DCs, the efficiency of this process is tigthly controlled by the kinin-degrading activity of ACE.
DC Activation by Kinins are Critically Required for Generation of Immunoprotective CD4
+ and CD8 + T Cells
Although the footpad infection model allowed us to dissect the activation pathways underlying TCT-evoked inflammation, the animals were resistant to acute infection, thus precluding analysis of the role of the TLR2/CXCR2/ B 2 KR axis in host resistance. We therefore addressed this issue by turning to the more traditional i.p. infection model [117] . As illustrated in Fig. (1) , we predicted that plasma proteins would diffuse freely to secondary lymphoid tissues (such as the spleen) of acutely infected mice. According to our working hypothesis, (i) extracellular T. cruzi would have direct access to blood-borne kininogens (ii) kinins would be released (via cruzipain) in the proximity of conventional CD11c + DCs residing in the spleen parenchyma [117] . Strikingly, B 2 KR-deficient (B6) mice succumbed, while wild type infected mice resisted, as expected [117] . Analysis of the parasite tissue burden in the heart revealed that it was significantly increased in BK 2 R -/-mice. Notably, the heigthened susceptibility of cardiac B 2 KR -/-tissues was paralleled by a signficant drop in the frequencies of intracardiac antigen-specific IFN--producing T cells in B 2 KR -/-mice. Surprisingly, we found similar frequencies of antigen-specific effector CD8 + T cells and CD4 + T cells in the spleen of wild-type and BK 2 R-deficient mice, suggesting that the lymphoid compartment of the mutant strain was well preserved at early stages the infection [117] . However, as the acute infection progressed, there was a sharp decline in the frequency of type-1 effector cells in B 2 KR -/-mice, both in lymphoid and cardiac tissues (more accentuated) [117] . Notably, the decayed T H 1 response of B 2 KR-deficient mice was accompanied by a rise in the pro-inflammatory T H 17 subset [117] , implying that B 2 KR signaling prevents induction and/or expansion of T H 17 type cells in acutely infected mice. Importantly, the hypothesis that DC signaling via B 2 KR is critically required for induction of protective effector T cells [117] . Adding weight to these observations, the analysis of CD11c + DC interaction with TCTs showed that IL-12 and co-stimulatory molecules (CD86, CD80, CD40) were strongly upregulated in wild type DCs, but not in B 2 KR -/-DCs. Moreover, parasites pre-treated with irreversible inhibitors of cruzipain failed to induce overt maturation of wild-type DCs, in keeping with the proposition that cruzipain enzymatically generates the B 2 KR agonist [117] . Future studies may determine if fluctuations in the levels of kinins in the myocardium of chronic chagasic patients may modulate the function of interstitial DCs. Of note, independent studies indicate that monocyte-derived human DCs express BKRs, but unlike the conventional CD11c + DCs isolated from the mouse spleen, these in vitro generated human APCs failed to undergo maturation upon stimulation with kinins [124] . Given the marked phenotypic heterogeneity of DCs [125] it remains to be determined if other human DC subtypes are responsive to kinins in the context of natural infection/inflammation.
Cruzipain May have Duals Functions in Chronic Heart Pathology
Early immunohistochemical studies revealed presence of cruzipain deposits in the myocardium of CCM patients [126] . Unlike their pH sensitive mammalian counterparts (cathepsin B/L), the lysosomal-like cysteine protease of T. cruzi is relatively stable in physiological pH. Depending on the availability of plasma proteins in the extravascular spaces, cruzipain may activate the kinin system. Low levels of kinins may stimulate nitric oxide via signaling of BK 2 R expressed by the endothelium lining, perhaps exerting beneficial effects to the chagasic heart. On the other hand, highlevels of kinins may evoke interstitial edema and aggravate inflammation and chronic immunopathology through the triggering of inducible BK 1 R subtype [85] . Another example of the multifaceted roles of cruzipain came from a recent study showing that cruzipain is capable of differentially cleaving three chemokines: CCL-2, CCL-12 and CCL-13 [127] . Analysis of the proteolyzed products showed that CCL-2 preserved its chemotactic activity, while the closely related CCL-12 and CCL-13 chemokines lost their agonist activity upon enzymatic treatment. Surprisingly, however, these authors found that a synthetic 14-mer cruzipainderived chemokine peptide displayed antagonistic function in assays of in vitro migration of monocytic cells and calcium flux release [127] . If confirmed by assays performed with living parasites, this mechanism may illustrate how cruzipain-mediated proteolysis may facilitate parasite adaptation in the inflamed/hostile tissue environment.
Whichever the origin of the natural substrates of cruzipain, it is likely that its extravascular functions may be shortlived. First, it is possible that cruzipain may undergo spontaneous inactivation due to oxidation of active-site cysteine [116, 118] , in the traditional intraperitoneal model of acute infection the plasma proteins (including kininogen molecules) diffuse freely through the spleen. The scheme depicts the immunostimulatory role of cruzipain as the TCTs (Dm28 strain) reach the splenic stroma [117] . Top, TCTs release kinins from cell-bound kininogens via cruzipain. Once released, the short-lived kinins act as endogenous danger signals, i.e., they activate B2KR expressed by splenic CD11c + DCs, thereby converting these APCs into type-1 inducers (through upregulation of CD80.CD86, CD40 and IL12). It is proposed that these antigen-loaded IL-12 producing DCs migrate to T cell rich areas of secondary lymphoid tissues (spleen), where they activate naïve T cells and/or memory T cells, thus generating immunoprotective (type-1) T cells that migrate to peripheral tissues, such as the heart [117] . residue. Second, the active protease may be entrapped by 2 -macroglobulin, and/or form tight-binding tri-molecular complexes by binding to one or two molecules of soluble kininogens [128] , as soon as these plasma proteins diffuse into peripheral sites of infection. Interestingly, the localization of cruzipain antigen overlapped with those of infiltrating macrophage-like cells expressing the 2 -macroglobulin scavenger receptor ( 2 MR/CD91) [126] . Interestingly in this context, Morrot and co-workers [126] showed that 2 -Mcruzipain complexes were rapidly internalized by human monocytes via the 2 MR/CD91 scavenger receptor [126] . Notably, the activation threshold of class II MHC-restricted CD4 + T cells from chronic chagasic patients was significantly reduced as result of efficient processing and presentation of cruzipain-derived peptides by these APCs [126] . In another study, Araujo-Jorge and co-workers [129] reported that T. cruzi-infected mice deficient in 2 -macroglobulin genes developed an exacerbated myocarditis. Of further interest, levels of serum antibodies against T. cruzi were substantially decreased in the 2 M -/-mice [129] . These results suggest that the 2 -macroglobulin, acting via 2 MR/CD91 enhaces T cell responses against cruzipain epitopes.
SUMMARY AND PERSPECTIVES
After three decades of research, the knowledge emerging from studies of cruzipain structure and function(s) suggests that the enzymatic versatility of this lysosomal cysteine protease is highly beneficial for host-parasite equilibrium. Apart from its intracellular role, TCTs exploit cruzipain to generate multiple infection-promoting signals through the cleavage of host and endogenous substrates (Fig. 1) . Although some T. cruzi strains may rely on the kinin-releasing activity of cruzipain to opportunistically invade cardiovascular cells via the B 1 KR pathway in the inflamed myocardium, recent studies in mice systemically infected by T. cruzi have linked the extravascular activation of the kinin system to the development of protective immunity. As illustrated in Fig. (2) , kinins released by TCTs induce generation/expansion of immunoprotective T cells via mechanisms involving activation of CD11c + DCs via the B 2 KR/IL-12 pathway. Studies of the dynamics of inflammation elicited by TCTs (subcutaneous model) revealed that extent of activation of the kinin cascade in peripheral tissues depends on the molecular interplay of several factors, namely: (i) tGPI-mucin/cruzipain (ii) the TLR2/CXCR2/B 2 KR axis and (iii) kinin-degrading enzymes, such as ACE. Future studies may clarify if dysfunctions in the regulation of cruzipain activity in extravascular sites of infection may influence pathogen outcome in the settings of human Chagas disease.
